PAVmed subsidiary Lucid Diagnostics closes 14.4M share offering raising ~$16.1M net

PAVmed Inc.

Lucid Diagnostics closed sale of 14,375,000 shares at $1.20 each, including full exercise of underwriters' option.
Net proceeds expected to be approximately $16.1 million after underwriting discounts and expenses.
Proceeds will be used for working capital and general corporate purposes.
Offering was made under Lucid's existing shelf registration statement (Form S-3) and prospectus supplement dated April 9, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.